Abselion

Executive Summary

Abselion is a UK-based biotechnology company founded in 2021 that has developed the Amperia™ instrument, an automated electrochemical sensing platform for rapid, accurate protein quantification and binding assays. The technology enables real-time measurement of antibodies, AAV capsids, and His-tagged proteins directly from crude samples, eliminating analytical delays in research and development workflows. By providing a faster, more accessible alternative to traditional methods like ELISA or SPR, Abselion aims to accelerate bioprocess development and quality control in oncology and immunology. While the company is early-stage with no disclosed funding or revenue, its product addresses a critical bottleneck in biologics analytics, offering potential value to pharmaceutical and contract research organizations. The Amperia™ platform has the potential to streamline workflows and reduce costs, positioning Abselion for growth as the biopharma industry increasingly prioritizes real-time monitoring and automation.

Upcoming Catalysts (preview)

• Q4 2026Commercial Launch of Amperia™ Instrument70% success
• Q1 2027Strategic Partnership with Biopharma or CRO40% success
• Q2 2027Receipt of First Major Purchase Orders50% success